Answers are grounded in this paper and cite their sources.
9028 Background: Atezolizumab (atezo, MPDL3280A), a humanized engineered mAb, is the first anti-PD-L1 agent to show improved OS vs docetaxel (doc) in NSCLC. These results correlate with PD-L1 expression on tumor cells (TC) and/or tumor-infiltrating immune cells (IC) and have shown improvement over time as reflected by the continued late separation of OS curves. Methods: Pts were randomized to receive atezo 1200 mg IV q3w or doc 75 mg/m2IV q3w. Tumors were prospectively evaluated for PD-L1 expression using the SP142 IHC assay and scored from low to high (0-3). Gene expression was analyzed using a Fluidigm platform. The primary endpoint was OS and the primary analysis included 173 events among 287 randomized pts (event/patient ratio [EPR] 60%; min follow up 13 mo). Here we present data as of Dec 1, 2015 with a min follow up of 20 mo. Results: With longer follow up and 200 events (EPR 70%) further separation in survival curves and improvement in OS HR were seen for atezo over doc for ITT (HR 0.69, 95% CI 0.52-0.92) and across PD-L1 and histology subgroups (Table). Longer mDOR was seen for atezo vs doc (18.6 vs 7.2 mo). Improved OS with atezo over doc correlated with high tumor expression of Teff /IFNγ-associated genes (unstratified HR 0.52, 95% CI 0.32−0.83). Atezo continues to have a tolerable safety profile distinct from doc. Conclusions: Extended follow up reveals further separation late in OS curves and increased benefit with atezo monotherapy vs doc. Relative to the primary analysis, OS benefit is improved in ITT and PD-L1 subgroups, including TC0 and IC0, and in pts with squamous NSCLC. In addition, PD-L1 expression measured by IHC and the tumor Teff /IFNγ gene signature, which reflects pre-existing immunity, can identify pts most likely to benefit from atezo. Clinical trial information: NCT01903993. OS Atezo Doc HRa 95% CI PValueb n Median, mo n Median, mo ITT 144 12.6 143 9.7 0.69 0.52-0.92 .011 TC3 or IC3 24 NRc 23 11.1 0.45 0.22-0.95 .033 TC2/3 or IC2/3 50 15.1 55 7.4 0.50 0.31-0.80 .003 TC1/2/3 or IC1/2/3 93 15.1 102 9.2 0.59 0.41-0.83 .003 TC0 and IC0 51 9.7 41 9.7 0.88 0.55-1.42 .601 Squamous 49 10.1 48 8.6 0.66 0.41-1.05 .075 Nonsquamous 95 14.8 95 10.9 0.69 0.49-0.98 .039 aStratified for ITT, unstratified for subgroups bDescriptive only cNot reached
No takes yet. Share an insight, caveat, or question.
Smith et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: